Ng-Test® CARBA 5, distributed by Hardy Diagnostics, is the only FDA-cleared, phenotypic, rapid, lateral flow assay that meets the new CLSI® 2025 M100™ guidelines. “These assays should identify and ideally differentiate the presence of specific carbapenemase types (eg. KPC, NDM, OXA-48, VIM, IMP).” * 2025 CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing, Table 2A-1. *